Drug Information

General Information
Drug ID
DR00693
Drug Name
Prazosin
Synonyms
1-(3-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; 2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline; 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine; 4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone; CP-12299; Furazosin; Hypovase (TN); Justac; Lentopres; Minipress (TN); Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-(8CI); Piperazine,1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-(9CI); Prazocin; Prazosin (INN); Prazosin HCl; Prazosin [INN:BAN]; Prazosina; Prazosina [INN-Spanish]; Prazosine; Prazosine [INN-French]; Prazosinum; Prazosinum [INN-Latin]; TNP00312; Vasoflex (TN); [3H]-Prazosin; [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone
Drug Type
Small molecular drug
Indication High blood pressure [ICD11: BA00] Approved [1]
Severe congestive heart failure [ICD11: BD10] Approved [1]
Therapeutic Class
Antihypertensive Agents
Structure
3D MOL 2D MOL
Formula
C19H21N5O4
Canonical SMILES
COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC
InChI
InChI=1S/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)
InChIKey
IENZQIKPVFGBNW-UHFFFAOYSA-N
CAS Number
CAS 19216-56-9
Pharmaceutical Properties Molecular Weight 383.4 Topological Polar Surface Area 107
Heavy Atom Count 28 Rotatable Bond Count 4
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 8
XLogP
2
PubChem CID
4893
PubChem SID
11112649 , 11112650 , 11113367 , 11120245 , 11120733 , 11121221 , 11121703 , 11122183 , 11335550 , 11360789 , 11362790 , 11363716 , 11365352 , 11366278 , 11367914 , 11368840 , 11370831 , 11370832 , 11371821 , 11373515 , 11374104 , 11376076 , 11377002 , 11406810 , 11461761 , 11466975 , 11468095 , 11485033 , 11486809 , 11489105 , 11490367 , 11492298 , 11494636 , 14804776 , 26751613 , 26751614 , 29223971 , 4500854 , 46508594 , 47364941 , 47364942 , 47588782 , 47662032 , 47662033 , 47662034 , 47662035 , 7980376 , 8153011 , 841974 , 9572
ChEBI ID
ChEBI:8364
TTD Drug ID
D0WV3U
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
OCT-1 Transporter Info Organic cation transporter 1 Substrate [3]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
Drug-Transporter Activity Data
Drug-Transporter Activity Data P-GP Transporter Info Km = 20 microM High five cells-MDR1 [4]
References
1 Prazosin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats. Brain Res. 2011 Jan 25;1370:238-45.
3 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
4 Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10594-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.